OCX 909
Alternative Names: Anti-Chi3l1/CTLA-4 bi-specific mAb; OCX-909Latest Information Update: 07 Aug 2023
Price :
$50 *
At a glance
- Originator Brown University
- Developer Ocean Biomedical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Glycoprotein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma
- Research Cancer; Malignant melanoma